The Global NASH Congress – Slide release
Posted 23rd May 2018 by Jane Williams
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.
NASH – The Silent Killer You’ve Never Heard Of
Posted 12th February 2018 by Jane Williams
Silent killers such as diabetes, high cholesterol and hypertension have been well discussed for many years. While non-medical professionals may not understand the pathophysiology of these diseases, most people can appreciate that they are harmful conditions which require treatment. Worldwide, nonalcoholic fatty liver disease (NAFLD) is estimated to affect more than 1 billion people; so why is nobody talking about it?
Susceptibility to Alcohol Induced Liver Injury: Driven by Gut Microbiota?
Posted 6th January 2017 by Jane Williams
Over the past decade, the intestinal microbiota has increasingly been recognised as a critical factor in health and disease. My research focuses on the role of the gut microbiome in metabolic diseases and my main aim is to prove causality. Most studies describe the gut microbiota from patients and compare it to healthy controls.